Our long term objectives are to identify gene mutations that cause obesity in humans and to understand their pathogenic effects. We have previously demonstrated that mutations in the Melanocortin-4 receptor (MC4-R), a hypothalamus expressed gene implicated in the central regulation of food intake, cause a common form of obesity in humans. This research proposal focuses on the pro-opiomelanocortin (POMC) gene. This gene is expressed in the arcuate nucleus of the hypothalamus and encodes the physiologic agonist ligands of the MC4R. Homozygous null mutations in the POMC gene result in a rare form of obesity associated with adrenal insufficiency and alterations in hair pigmentation. Recent results in the literature as well as our preliminary findings suggest that heterozygous POMC mutations can predispose to common obesity. Our hypothesis is that a significant number of common severe obesity cases are due to such heterozygous mutations in the POMC gene. To investigate this hypothesis we propose the following specific aims:
Aim 1) To determine the prevalence and association of rare POMC gene variants in severe and or early onset human obesity. We will evaluate the prevalence of rare POMC mutations in severe obesity by systematically screening cohorts of severely obese children and adults for mutations in the POMC coding sequence. We will verify the absence of such mutations in non-obese controls. We will analyze the segregation of obesity with the mutations in the families of the probands. We will search for specific phenotypes distinguishing obese POMC mutation carriers from other obese patients.
Aim 2) To determine the in vitro effects of obesity associated POMC mutations. Starting with the known obesity-associated heterozygous mutations in the POMC gene, we will systematically evaluate the effects of all the obesity-associated POMC mutations. Specifically we will: 2.1- Examine the effects of human obesity associated POMC mutations on the processing of POMC. 2.2- Examine the effects of mutated human obesity associated POMC derived peptides on MC4R and MC3R activation. 2.3- Test for a toxic effect of human obesity associated POMC mutations on primary cultures of neurons.
Aim 3) To determine the effects of obesity associated POMC mutations in vivo. To further confirm the pathogenicity of human obesity associated POMC mutations we will: 3.1- Evaluate the short term effects of mutated human obesity associated POMC derived peptides on food intake in rats. 3.2- Evaluate the long-term effects of transgenic over-expression of human obesity associated POMC mutations in mice. This work will be an additional step towards the genetic classification of obesity in humans and will contribute to the development of targeted preventive and therapeutic interventions based on the underlying genetic defects in the patients. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK068152-02
Application #
7122522
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Karp, Robert W
Project Start
2005-09-15
Project End
2008-07-31
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
2
Fiscal Year
2006
Total Cost
$303,277
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Aslan, I R; Ranadive, S A; Valle, I et al. (2014) The melanocortin system and insulin resistance in humans: insights from a patient with complete POMC deficiency and type 1 diabetes mellitus. Int J Obes (Lond) 38:148-51
Heymsfield, Steven B; Avena, Nicole M; Baier, Leslie et al. (2014) Hyperphagia: current concepts and future directions proceedings of the 2nd international conference on hyperphagia. Obesity (Silver Spring) 22 Suppl 1:S1-S17
Aslan, Ivy R; Campos, Guilherme M; Calton, Melissa A et al. (2011) Weight loss after Roux-en-Y gastric bypass in obese patients heterozygous for MC4R mutations. Obes Surg 21:930-4
Aslan, I R; Ranadive, S A; Ersoy, B A et al. (2011) Bariatric surgery in a patient with complete MC4R deficiency. Int J Obes (Lond) 35:457-61
Calton, Melissa A; Ersoy, Baran A; Zhang, Sumei et al. (2009) Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Hum Mol Genet 18:1140-7
Ranadive, Sayali A; Ersoy, Baran; Favre, Helene et al. (2009) Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin Endocrinol (Oxf) 71:388-93
Bromberg, Yana; Overton, John; Vaisse, Christian et al. (2009) In silico mutagenesis: a case study of the melanocortin 4 receptor. FASEB J 23:3059-69
Calton, Melissa A; Vaisse, Christian (2009) Narrowing down the role of common variants in the genetic predisposition to obesity. Genome Med 1:31
Clement, Karine; Dubern, Beatrice; Mencarelli, Monica et al. (2008) Unexpected endocrine features and normal pigmentation in a young adult patient carrying a novel homozygous mutation in the POMC gene. J Clin Endocrinol Metab 93:4955-62
Dubern, Beatrice; Lubrano-Berthelier, Cecile; Mencarelli, Monica et al. (2008) Mutational analysis of the pro-opiomelanocortin gene in French obese children led to the identification of a novel deleterious heterozygous mutation located in the alpha-melanocyte stimulating hormone domain. Pediatr Res 63:211-6

Showing the most recent 10 out of 11 publications